Redeye comments on Neola Medical’s update regarding the analysis of the Swedish clinical study. The device continues to demonstrate a solid safety profile, which is in line with expectations. We also note that the company intends to pursue a claim that the device can detect lung collapse. The updated timeline aligns well with our projections, resulting in no changes to our estimates. Furthermore, we view the upcoming dialogue with the FDA as important to monitor, as we expect it to provide greater clarity on the requirements for future clinical validation.
LÄS MER
